2 terminated, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Neihulizumab: new trials by email Literature Review of Neihulizumab trials Research Report on Neihulizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD) Neihulizumab, 3 mg/kg, Neihulizumab, 6 mg/kg, Neihulizumab, 9 mg/kg - Graft-versus-host Disease | Phase 1 | Completed | Sameem M. Abedin, MD | 12 | 2020-12-14 | 2024-10-01 |
| Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC ALTB-168 - Ulcerative Colitis | Phase 2 | Terminated | AltruBio Inc. | 24 | 2018-05-04 | 2024-01-05 |
| A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant AbGn-168H - Acute Graft Versus Host Disease | Phase 1 | Terminated | AbGenomics B.V Taiwan Branch | 4 | 2015-05-01 | 2017-03-30 |
Colitis, Ulcerative (1) · Graft vs Host Disease (1)
AbGenomics B.V Taiwan Branch (1) · AltruBio Inc. (1) · Sameem M. Abedin, MD (1)
United States (3) · Puerto Rico (1)
David T Rubin, MD (1) · Everett Meyer, MD (1) · Sameem Abedin, MD (1) · Shih-Yao Lin, MD, PhD (1)